Download MendeleyEvaluation of a Series of beta-Secretase 1 Inhibitors Containing Novel Heteroaryl-Fused-Piperazine Amidine Warheads.
Oehlrich, D., Peschiulli, A., Tresadern, G., Van Gool, M., Vega, J.A., De Lucas, A.I., Alonso de Diego, S.A., Prokopcova, H., Austin, N., Van Brandt, S., Surkyn, M., De Cleyn, M., Vos, A., Rombouts, F.J.R., Macdonald, G., Moechars, D., Gijsen, H.J.M., Trabanco, A.A.(2019) ACS Med Chem Lett 10: 1159-1165
- PubMed: 31413800
- DOI: https://doi.org/10.1021/acsmedchemlett.9b00181
- Primary Citation of Related Structures:
6OD6 - PubMed Abstract:
Despite several years of research, only a handful of β-secretase (BACE) 1 inhibitors have entered clinical trials as potential therapeutics against Alzheimer's disease. The intrinsic basic nature of low molecular weight, amidine-containing BACE 1 inhibitors makes them far from optimal as central nervous system drugs. Herein we present a set of novel heteroaryl-fused piperazine amidine inhibitors designed to lower the basicity of the key, enzyme binding, amidine functionality. This study resulted in the identification of highly potent (IC 50 ≤ 10 nM), permeable lead compounds with a reduced propensity to suffer from P-glycoprotein-mediated efflux.
Organizational Affiliation:
Medicinal Chemistry, Discovery Sciences, Neuroscience Biology, Janssen Research & Development, Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse, Belgium.
